Table 1.

Alemtuzumab in clinical trials

Study agents	Other agents	Disease	Dosage	Clinical trials	No Pts	Response	Reference
Alemtuzumab		High risk	30 mg	Phase II	93	CR:2%	[19]
						ORR:33%
Alemtuzumab	Dexamethasone	Untreated	30 mg	Phase II	131	CR:19/4/3%	[20]
		Relapsed				ORR:98/79/70%
		Refractory
Alemtuzumab	Rituximab	High risk	30 mg	Phase I	13	CR:64%	[21]
	PGG beta glucan					ORR:100%

Abbreviations. ORR overall response rate, CR complete response rate.